Cardiff Oncology Inc. Insider Trading

CRDF

⊜ Compare

Last 12 months

Insiders bought $1.12M on the open market and sold nothing.

Net open-market

+$1.12M

4 buys · 0 sales

Under a 10b5-1 plan

—

no sales

Insiders who bought / sold

2 / 0

executives and directors

Last open-market buy

Jul 2026

Jul 14, 2026

Get an email when CRDF's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jul 14	Gary W Pace Director	Bought	687,285	$1.46	$1M	51%	Form 4
Jul 14	Mani Mohindru Chief Executive Officer	Bought	34,364	$1.46	50K	139%	Form 4
Jun 18	Mani Mohindru Chief Executive Officer	Bought	24,703	$1.21	30K	New	Form 4
Jun 18	Gary W Pace Director	Bought	30,000	$1.22	37K	2.3%	Form 4
Jul 30, 2025	Gary W Pace Director	Bought 2 parts	290,000	$2.45 average	711K	12%	Form 4
Dec 16, 2024 – Dec 18, 2024	James E. Levine Chief Financial Officer	Bought 3 parts	7,716	$4.76 average	37K	13%	Form 4
Dec 12, 2024	Renee P Tannenbaum Director	Bought	10,000	$3.42	34K	100%	Form 4
Dec 11, 2024	Gary W Pace Director	Bought 2 parts	361,615	$2.60 average	940K	21%	Form 4

Jul 14
Gary W Pace
Director · bought 687,285 at $1.46
$1M
51% of stake
Jul 14
Mani Mohindru
Chief Executive Officer · bought 34,364 at $1.46
50K
139% of stake
Jun 18
Mani Mohindru
Chief Executive Officer · bought 24,703 at $1.21
30K
New position
Jun 18
Gary W Pace
Director · bought 30,000 at $1.22
37K
2.3% of stake
Jul 30, 2025
Gary W Pace
Director · bought 290,000 at avg $2.45
711K
12% of stake
Dec 16, 2024 – Dec 18, 2024
James E. Levine
Chief Financial Officer · bought 7,716 at avg $4.76
37K
13% of stake
Dec 12, 2024
Renee P Tannenbaum
Director · bought 10,000 at $3.42
34K
100% of stake
Dec 11, 2024
Gary W Pace
Director · bought 361,615 at avg $2.60
940K
21% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch CRDF, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with CRDF

CompareIntrinsic value

PALIPalisade Bio Inc.

$1.25+1.63%20

ARMPArmata Pharmaceuticals Inc.

$3.14+1.62%30

BCABBioAtla, Inc.

$2.00+0.00%0

CVMCel-Sci Corporation

$1.38-2.13%0

IMAImageneBio, Inc.

$4.10+1.99%10

ZIVOZivo Bioscience Inc.

$8.00+10.34%0

PROKProKidney Corp

$1.12+4.67%10

WINTWindtree Therapeutics Inc.

$0.00+0.00%10

Held by ETFs

CRDF is in 1 US ETF. The largest of them, with CRDF's weight in each:

iShares Micro-Cap ETFIWC0.02%of the fund

Spot a number that looks wrong? Check it in CRDF's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing CRDF

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.